Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot/Safety Study of sEphB4-HSA in Combination With a Hypomethylating Agent (HMA) for Patients With Relapsed or Refractory Myelodysplastic Syndrome (MDS) and AML Previously Treated With a Hypomethylating Agent

NCT03146871 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT03146871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03146871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot/Safety Study of sEphB4-HSA in Combination With a Hypomethylating Agent (HMA) for Patients With Relapsed or Refractory Myelodysplastic Syndrome (MDS) and AML Previously Treated With a Hypomethylating Agent
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Terminated
Start date
April 20, 2017
Completion date
March 27, 2019
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia arising from previous myelodysplastic syndrome, chronic myelomonocytic leukemia, previously treated myelodysplastic syndrome, recurrent acute myeloid leukemia with myelodysplasia-related changes, recurrent adult acute myeloid leukemia